Metastatic Breast Cancer | A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer

Metastatic Breast Cancer research study

What is the primary objective of this study?

Comparing Docetaxel Plus Fulvestrant With Docetaxel in Patients With Metastatic Breast Cancer

Who is eligible to participate?

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Metastatic Breast Cancer

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Docetaxel75mg/m2 D2 every 21 days

Drug:Fulvestrant500mg D1, D15, D29, D57, every 28 days later

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Docetaxel Plus FulvestrantDocetaxel:75mg/m2 D2 every 21 days Fulvestrant:500mg D1, D15, D29, D57, every 28 days later

DocetaxelDocetaxel:75mg/m2 D2 every 21 days

Study Status


Start Date: April 2014

Completed Date: July 2017

Phase: Phase 2

Type: Interventional


Primary Outcome: Progression Free Survival

Secondary Outcome: Overall Response Rate

Study sponsors, principal investigator, and references

Principal Investigator: Xichun Hu, MD, PhD

Lead Sponsor: Fudan University


More information:

Discuss Taxotere